tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2024 Jul 29.
doi: 10.1080/14760584.2024.2383343. Online ahead of print. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom
Cale Harrison[SUP] 1 [/SUP], Rebecca Butfield[SUP] 1 [/SUP], Ben Yarnoff[SUP] 2 [/SUP], Jingyan Yang[SUP] 3 [/SUP]
Affiliations
Background: Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose of an adapted vaccine in the United Kingdom (UK).
Methods: A Markov-decision tree model estimated the outcomes of vaccination strategies targeting various age and risk groups in the UK. Age-specific data derived from published sources were used. The model estimated case numbers, deaths, hospitalizations, medical costs, and societal costs. Scenario analyses were conducted to explore uncertainty.
Results: Vaccination targeting individuals aged ≥65 years and the high-risk population aged 12-64 years was estimated to avert 701,549 symptomatic cases, 5,599 deaths 18,086 hospitalizations 56,326 post-COVID condition cases, and 38,263 lost quality-adjusted life years (QALYs), translating into direct and societal cost savings of £112,174,054 and £542,758,682, respectively. The estimated economically justifiable price at willingness-to-pay thresholds of £20,000 and £30,000 per QALY was £43 and £61, respectively, from the payer perspective and £64 and £82, respectively, from the societal perspective. Expanding to additional age groups improved the public health impact.
Conclusions: Targeting individuals aged ≥65 years and those aged 12-64 years at high risk yields public health gains, but expansion to additional age groups provides additional gains.
Keywords: Adapted vaccine; Booster vaccine; COVID-19; SARS-CoV-2; United Kingdom.
. 2024 Jul 29.
doi: 10.1080/14760584.2024.2383343. Online ahead of print. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom
Cale Harrison[SUP] 1 [/SUP], Rebecca Butfield[SUP] 1 [/SUP], Ben Yarnoff[SUP] 2 [/SUP], Jingyan Yang[SUP] 3 [/SUP]
Affiliations
- PMID: 39072472
- DOI: 10.1080/14760584.2024.2383343
Background: Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose of an adapted vaccine in the United Kingdom (UK).
Methods: A Markov-decision tree model estimated the outcomes of vaccination strategies targeting various age and risk groups in the UK. Age-specific data derived from published sources were used. The model estimated case numbers, deaths, hospitalizations, medical costs, and societal costs. Scenario analyses were conducted to explore uncertainty.
Results: Vaccination targeting individuals aged ≥65 years and the high-risk population aged 12-64 years was estimated to avert 701,549 symptomatic cases, 5,599 deaths 18,086 hospitalizations 56,326 post-COVID condition cases, and 38,263 lost quality-adjusted life years (QALYs), translating into direct and societal cost savings of £112,174,054 and £542,758,682, respectively. The estimated economically justifiable price at willingness-to-pay thresholds of £20,000 and £30,000 per QALY was £43 and £61, respectively, from the payer perspective and £64 and £82, respectively, from the societal perspective. Expanding to additional age groups improved the public health impact.
Conclusions: Targeting individuals aged ≥65 years and those aged 12-64 years at high risk yields public health gains, but expansion to additional age groups provides additional gains.
Keywords: Adapted vaccine; Booster vaccine; COVID-19; SARS-CoV-2; United Kingdom.